An observational study in Hepatitis C, sponsored by Fundacion IMIM. Completed at 104 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-12.
Sponsored by Fundacion IMIM · Observational
The purpose of this study is to describe the management of patients with chronic hepatitis C and previous treatment failure.
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
This study's enrollment of 2,178 is above the median of 250 across 687 observational studies indexed under Hepatitis A.
Browse Hepatitis A studies →Fundacion IMIM is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients of both sexes older than 18 years old with hepatitis C who had previously failed to the standard therapy.
Exclusion Criteria:
Describe the management of patients with chronic hepatitis C and previous treatment failure
Time frame: 6 years
To know the frequency of the causes for not responding to the previous treatment: lack of adherence to treatment, incomplete dose of antiviral treatment, insufficient treatment duration or treatment resistance.
Time frame: 6 years
To assess the percentage of patients with previous treatment failure who are not candidates for re-treatment and its causes.
Time frame: 6 years
To evaluate the implementation of current recommendations based on the cause of the previous therapeutic failure, in patients with chronic hepatitis C in whom a new course of the antiviral treatment is decided to be administered.
Time frame: 6 years
To know the causes of the dose modifications and withdrawal of treatment during the follow-up period in patients who start re-treatment.
Time frame: 6 years
To know the percentage of patients that achieve sustained viral response when implementing the recommendations based on the cause of the previous therapeutic failure.
Time frame: 6 years
To determine the presence of the polymorphism rs12979860 in the gene IL 28B located on chromosome 19.
The rs12979860 polymorphism in the gene IL 28B that is located on chromosome 19 showed to be strongly associated with the development of sustained viral response (SVR) in patients with chronic hepatitis C treated with PEG-IFN-α/RBV. Patients with this polymorphism clear the virus more easily.
Time frame: 6
Compare the management of patients with chronic hepatitis C prior treatment failure before and after the appearance of new treatments.
Time frame: 3
Showing the first 100 of 104 sites.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion IMIM